Antihistamines: Topical vs oral administration

Clinical and Experimental Allergy, Supplement

Volumn 26, Issue 3, 1996, Pages 11-17

  Davies, R J ^a   Bagnall, A C ^a   McCabe, R N ^a   Calderon, M A ^a   Wang, J H ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; AZELASTINE; BECLOMETASONE DIPROPIONATE; CETIRIZINE; INTERCELLULAR ADHESION MOLECULE 1; LEVOCABASTINE; TERFENADINE;

ALLERGIC RHINITIS; CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; HUMAN; INTRANASAL DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; HISTAMINE H1 ANTAGONISTS; HUMANS; RESPIRATORY HYPERSENSITIVITY;

EID: 0029948697     PISSN: 09602178     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (35)

1. Wang JH, Devalia JL, Duddle JM, Hamilton SA, Davies RJ. Effect of six hour exposure to nitrogen dioxide on early-phase nasal response to allergen challenge in patients with a history of seasonal allergic rhinitis. J Allergy Clin Immunol 1995; 96:669-76.
2. Calderon MA, Devalia JL, Sapsford RJ, Davies RJ. Cytokine profiles of cultured nasal epithelial cells from atopic rhinitic, atopic non-rhinitic and non-atopic non-rhinitic subjects. J Allergy Clin Immunol 1995; 95(1 part 2): (abstr) 257.
3. Devalia JL, Godfrey RWA, Sapsford RJ et al. No effect of histamine on human bronchial epithelial cell permeability and tight junctional integrity in-vitro. Eur Respir J 1994; 7:1958-65.
4. Persson CGA, Erjefalt I, Alkner LJ et al. Plasma exudation as a first line respiratory mucosal defence. Clin Exp Allergy 1991; 21:17-24.
5. Davies RJ, Trigg C. Rhinitis: pathophysiology and classification. In: Holgate ST, Church M. eds., Allergy. London: Gower Medical Publications, 1993:17. 7.
6. 1 antagonist loratadine on histamine release from human basophils. Int Arch Allergy Immunol 1994; 105:12-7.
7. Campbell AM, Chanez P, Marty-Ane C et al. Modulation of eicosanoid and histamine release from human dispersed lung ceils by terfenadine. Allergy 1993; 48:125-9.
8. Berthon B, Taudou G, Combettes L et al. In-vitro inhibition by loratadine and descarboxyethoxyloratadine, of histamine release from human basophils and of histamine release and intracellular calcium fluxes in rat basophilic leukaemia cells. Biochem Pharmacol 1994; 47:789-94.
9. Kreutner W, Chapman RW, Gulbekian A, Siegel MI. Antiallergic activity of loratadine, a non-sedating anti-histamine. Allergy 1987; 42:57-63.
10. Fadel R, Herpin-Richard M, Rihoux JP, Henocq E. Inhibitory effect of cetirizine 2HCl on eosinophil migration in-vivo. Clin Allergy 1987; 17:373-9.
11. Little MM, Casale TB. Azelastine inhibits Ig-E mediated human basophils histamine release. J Allergy Clin Immunol 1989; 83:862-5.
12. Canonica GW, Ciprandi G, Buscaglia S, Pesce G, Bagnasco M. Adhesion molecules of allergic inflammation: recent insights into their functional roles. Allergy 1994; 49:135-41.
13. 1 receptor antagonists assessed by nasal challenge. J Allergy Clin Immunol 1988; 82:881-7.
14. Ciprandi G, Buscaglia S, Pesce GP, Marchesi E, Canonica GW. Protective effect of loratadine on specific conjunctival provocation test. Int Arch Allergy Appl Immunol 1991; 96:344-7.
15. Ciprandi G, Buscaglia S, Marchesi E et al. Protective effect of loratadine in late phase reaction induced by conjunctival provocation test. Int Arch Allergy Appl Immunol 1993; 100:185-9.
16. Pazdrak K, Gorski P, Ruta U. Inhibitory effect of levocabastine on allergen-induced increase of nasal reactivity to histamine and cell influx. Allergy 1993; 48:598-601.
17. 1-antihistamine well suited for topical application. In: Mygind N, Naclerio RM, eds. Rhinoconjunctivitis: new perspectives in topical treatment. Toronto: Hogrefe & Huber, 1989:27-34.
18. Wegner CD, Gundel RH, Reilly P et al. Intercellular adhesion molecule-1 (ICAM-1) in the pathogenesis of asthma. Science 1990; 247:456-9.
19. 1-receptor antagonists on adhesion molecules and cellular traffic. Allergy 1995; 50:17-23.
20. Buscaglia S, Catrullo A, Ciprandi G et al. Levocabastine eye drops reduce ICAM-1 expression both in-vitro and in-vivo. Allergy 1995; 50(suppl): (abstr)79.
21. Pronzato G, Ricca V, Varese P et al. Evaluation of anti-allergic activity of azelastine nasal spray. Allergy 1995; 50 (suppl): (abstr)69.
22. Nielsen L, Johnsen CR, Bindsley-Jensen C, Poulsen LK. Efficacy of acrivastine in the treatment of allergic rhinitis during natural pollen exposure: onset of action. Allergy 1994; 49:630-6.
23. Janssens MM-L, Vanden Bussche G. Levocabastine: an effective topical treatment of allergic rhinoconjunctivitis. Clin Exp Allergy 1991; 21(suppl 2):29-36.
24. Janssens MM-L. Levocabastine: a new topical approach for the treatment of paediatric allergic rhinoconjunctivitis. Rhinology 1992; 13(suppl):39-49.
25. Thomas KE, Ollier S, Ferguson H, Davies RJ. The effect of intranasal azelastine, Rhinolast, on nasal airways obstruction and sneezing following provocation testing with histamine and allergen. Clin Exp Allergy 1992; 22:642-7.
26. Bahmer FA, Ruprecht KW. Safety and efficacy of topical levocabastine compared with oral terfenadine. Ann Allergy 1994; 72:429-34.
27. Wihl JA, Rudblad S, Kjellen H, Blychert LA. Levocabastine eye drops versus sodium cromoglycate in seasonal allergic conjunctivitis. Clin Exp Allergy 1991(suppl 2):37-8.
28. Gastpar H, Nolte D, Aurich R et al. Comparative efficacy of azelastine nasal spray and terfenadine in seasonal and perennial rhinitis. Allergy 1994; 49:152-8.
29. Davies RJ, Lund VJ, Harten-Ash VJ. The effect of intranasal azelastine and beclomethasone on the symptoms and signs of nasal allergy in patients with perennial allergic rhinitis. Rhinology 1993; 31:159-64.
30. 1 antagonists, astemizole and terfenadine. Br J Clin Pharmacol 1982; 13:199.
31. Weiler JM, Donnelley A, Campbell BH et al. Multicentre double-blind, multiple dose, parallel grouping efficacy and safety trial of azelastine, chlorpheniramine and placebo in the treatment of spring allergic rhinitis. J Allergy Clin Immunol 1988; 82:801.
32. Falliers CJ, Brandon M, Buchman E et al. Cetirizine therapy in seasonal allergic rhinitis: a dose response study. Ann Allergy 1988; 60:166.
33. Arriaga F, Rombaut N. Absence of central effects with levocabastine eye drops. Allergy 1990; 45:552-4.
34. Dechant KL, Goa KL. Levocabastine: a review of its pharmacological properties and therapeutic potential as a topical antihistamine in allergic rhinitis and conjunctivitis. Drugs 1991; 41:202-24.
35. Grossman J, Halverson PC, Meltzer EO et al. Double-blind assessment of azelastine in the treatment of perennial allergic rhinitis. Ann Allergy 1994; 73:141-6.